Comments to USPSTF On Screening

On October 5, 2015 the U.S. Preventive Services Task Force (USPSTF) issued draft recommendations for colorectal cancer screening with the purpose of receiving public input. Below are the official comments from Fight Colorectal Cancer. October 28, 2015 Dear USPSTF Review Committee: Fight Colorectal Cancer, along…

Read Full Post

Cancer-Related Fatigue: Real, Treatable, and Under-Treated

Life-altering fatigue will affect 80% of people getting chemotherapy or radiation therapy, plus most people who have metastatic cancer, and even many survivors long after treatment is done. Yet fatigue in cancer patients has been under-reported, under-diagnosed, and under-treated, according to an expert panel convened…

Read Full Post

Erbitux Approved as First-Line Treatment

The FDA has approved Erbitux™ (cetuximab) in combination with FOLFIRI for first-line treatment of patients with metastatic colorectal cancer whose tumors have a wild-type (WT) KRAS gene.  Erbitux was first approved in 2004 for patients whose cancer was not responding to available treatments. FDA’s action was…

Read Full Post

Colorectal Cancer News in Brief: December 21

  Briefly It’s been tested, and it hurts less to rip a bandaid off fast. NCCN has updated their guidelines for colon and rectal cancer to include testing for BRAF mutations in patients with metastatic colorectal cancer. FDA announced a recall of some lots of…

Read Full Post